The Top 5 Biosimilar Articles for the Week of March 22

Here are the top 5 biosimilar articles for the week of March 22, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 22, 2021.

Number 5: Peter Bach, MD, MAPP, and his Drug Pricing Lab at Memorial Sloan Kettering (MSK) argue profit caps will do better than the current biosimilar system.

Number 4: Animal toxicology studies contribute little to demonstrations of biosimilarity and yet these studies frequently must be done to satisfy international regulatory requirements, investigators conclude.

Number 3: Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.

Number 2: AbbVie, the maker of originator adalimumab, has filed a suit against biosimilar developer Alvotech for unlawful receipt of trade secrets related to the production of its very successful high-concentration adalimumab formulation.

Number 1: Merck said it is taking steps to register its planned biosimilar and women’s health products spinoff as a publicly traded stock corporation.

To read all of these articles and more, visit centerforbiosimilars.com.